A team from Helmholtz Munich, the German Center for Diabetes Research (DZD) and Ludwig-Maximilians-Universität München (LMU) has now discovered why the simultaneous activation and blockade of the GIP receptor promotes weight loss. The new findings could pave the way for more targeted anti-obesity drugs. The latest results have now been published in Nature Metabolism.
“Our study shows that GIPR agonists and antagonists both lead to weight loss and reduced food intake. However, this occurs via completely different and independent mechanisms. Our work explains how GIPR agonists and antagonists act in the brain to regulate energy metabolism,” says first author Prof. Dr. Timo Müller.
